The Role of Human Herpesvirus 8 Molecular Characterization in the Management of HIV Infected Patients Diagnosed with Malignancies Associated with Its Infection

DOI: 10.4236/wja.2013.33030   PDF   HTML     3,586 Downloads   5,203 Views   Citations


Despite the progress has been reached with Human herpesvirus 8 (HHV-8) research, there are gaps in the knowledge of viral induced oncogenesis. The aim of the present study was to identify possible associations between HHV-8 subtypes, HHV-8 loads and clinical manifestations of HIV infected patients diagnosed with different malignancies associated with HHV-8 infection. Forty six HIV-1 infected individuals diagnosed with different HHV-8 associated diseases were studied [37 epidemic Kaposis sarcoma (KS), 3 pleural effusion lymphoma (PEL); 5 peripheral lymphadenopathies (PL); 1 Hodgkin’s lymphoma (HL); 1 non Hodgkin’s lymphoma (NHL)]. HHV-8 loads were determined by quantitative real time PCR (qRT-PCR) whilst HHV-8 subtypes were determined by open-reading frame (ORF)-K1 gen genotyping. HHV-8 subtypes B, A, C, A5 and E were exhibited by 31.8%, 23.4%, 19.1%, 17% and 8.5% of the studied patients, respectively. The median HHV-8 viral load did not differ between subtypes (p > 0.05) but HHV-8 viral loads were significantly higher in PEL than in epidemic KS lesion or lymph nodes (p = 0.04). Subtype B was detected in 60% of patients with B cell lymphoma (NHL, PEL and HL) whereas subtype E was only detected in patients with epidemic KS diagnosis. Our data suggest that HHV-8 DNA quantification instead of subtype identification could be used as a surrogate marker for monitoring its infection, not only in epidemic KS patients but also in HIV infected individuals with lymphoproliferative disorders.

Share and Cite:

M. Ariel, K. Vivian, B. Orestes, C. Virginia, A. Yoandra, A. Yoan, V. Denis, J. Narciso, C. Iraida, F. Gilberto, U. Yaumara, C. Odalys, Á. Alina and U. Hengge, "The Role of Human Herpesvirus 8 Molecular Characterization in the Management of HIV Infected Patients Diagnosed with Malignancies Associated with Its Infection," World Journal of AIDS, Vol. 3 No. 3, 2013, pp. 221-230. doi: 10.4236/wja.2013.33030.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] D. Ganem, “Kaposi’s Sarcoma-Associated Herpesvirus,” In: D. M. Knipe and P. M. Howley, Eds., Fields Virology, 5th Edition, Lippincott Williams & Wilkins, 2007, p. 2847-2888.
[2] J. C. Zong, D. M. Ciufo, D. J. Alcendor, X. Wan, J. Nicholas, P. J. Browning, et al., “High-Level Variability in the ORF-K1 Membrane Protein Gene at the Left End of the Kaposi’s Sarcoma-Associated Herpesvirus Genome Defines Four Major Virus Subtypes and Multiple Variants or Clades in Different Human Populations,” Journal of Virology, Vol. 73, No. 5, 1999, pp. 4156-4170.
[3] S. Franceschi, L. D. Maso, M. Rickenbach, J. Polesel, B. Hirschel, M. Cavassini, et al., “Kaposi Sarcoma Incidence in the Swiss HIV Cohort Study before and after Highly Active Antiretroviral Therapy,” British Journal of Cancer, Vol. 99, No. 5, 2008, pp. 800-804. doi:10.1038/sj.bjc.6604520
[4] T. Maurer, M. Ponte and K. Leslie, “HIV-Associated Kaposi’s Sarcoma with a High CD4 Count and a Low Viral Load,” New England Journal of Medicine, Vol. 357, No. 13, 2007, pp. 1352-1353. doi:10.1056/NEJMc070508
[5] V. Kouri, A. Marini, R. Doroudi, S. Nambiar, M. E. Rodriguez, V. Capo, et al., “Molecular Epidemiology of Kaposi’s Sarcoma Herpesvirus (KSHV) in Cuban and German Patients with Kaposi’s Sarcoma (KS) and Asymptomatic Sexual Contacts,” Virology, Vol. 337, No. 2, 2005, pp. 297-303. doi:10.1016/j.virol.2005.04.033
[6] V. Kouri, X. Liang, M. E. Rodriguez, V. Capo, S. Resik, J. Barrios, et al., “Molecular Epidemiology and KSHV K1 Subtypes in a Cuban AIDS-Kaposi’s Sarcoma Population,” Aids, Vol. 19, No. 9, 2005, pp. 984-987. doi:10.1097/01.aids.0000171416.07034.d6
[7] V. Kouri, P. A. Martinez, V. Capo, O. Blanco, M. E. Rodriguez, N. Jimenez, et al., “Kaposi’s Sarcoma and Human Herpesvirus 8 in Cuba: Evidence of Subtype B Expansion,” Virology, Vol. 432, No. 2, 2012, pp. 361-369. doi:10.1016/j.virol.2012.06.014
[8] R. Kumar, A. Abbas, A. DeLancey and E. Malone, “Diseases of the Immune System,” In: R. Kumar, A. Abbas, A. DeLancey and E. Malone, Eds., Robbins and Cotran Pathologic Basis of Disease, 8 Edition, Elsevier Inc., 2010, pp. 183-257.
[9] F. Watzinger, M. Suda, S. Preuner, R. Baumgartinger, K. Ebner, L. Baskova, et al., “Real-Time Quantitative PCR Assays for Detection and Monitoring of Pathogenic Human Viruses in Immunosuppressed Pediatric Patients,” Journal of Clinical Microbiology, Vol. 42, No. 11, 2004, pp. 5189-5198. doi:10.1128/JCM.42.11.5189-5198.2004
[10] V. Kouri, P. A. Martinez, O. Blanco, V. Capo, M. E. Rodriguez, C. Dovigny Mdel, et al., “Simultaneous Quantification of Human Herpesvirus 8 DNA by Real Time PCR in Different Tissues of HIV Infected Cuban Patients with Kaposi’s Sarcoma,” Herpesviridae, Vol. 1, No. 1, 2010, p. 3. doi:10.1186/2042-4280-1-3
[11] M. Schmitz, C. Scheungraber, J. Herrmann, K. Teller, M. Gajda, I. B. Runnebaum, et al., “Quantitative Multiplex PCR Assay for the Detection of the Seven Clinically Most Relevant High-Risk HPV Types,” Journal of Clinical Virology, Vol. 44, No. 4, 2009, pp. 302-307. doi:10.1016/j.jcv.2009.01.006
[12] K. Tamura, J. Dudley, M. Nei and S. Kumar, “MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) Software Version 4.0,” Molecular Biology and Evolution, Vol. 24, 2007, pp. 1596-1599. doi:10.1093/molbev/msm092
[13] M. Clamp, J. Cuff, S. M. Searle and G. J. Barton, “The Jalview Java Alignment Editor,” Bioinformatics, Vol. 20, 2004, pp. 426-427. doi:10.1093/bioinformatics/btg430
[14] D. Posada and K. A. Crandall, “MODELTEST: Testing the Model of DNA Substitution,” Bioinformatics, Vol. 14, 1998, pp. 817-818. doi:10.1093/bioinformatics/14.9.817
[15] N. H. Dukers and G. Rezza, “Human Herpesvirus 8 Epidemiology: What We Do and Do Not Know,” Aids, Vol. 17, No. 12, 2003, pp. 1717-1730. doi:10.1097/00002030-200308150-00001
[16] A. G. Marcelin, J. Motol, A. Guihot, E. Caumes, J. P. Viard, E. Dussaix, et al., “Relationship between the Quantity of Kaposi Sarcoma-Associated Herpesvirus (KSHV) in Peripheral Blood and Effusion Fluid Samples and KSHV-Associated Disease,” Journal of Infectious Disease, Vol. 196, No. 8, 2007, pp. 1163-1166. doi:10.1086/521625
[17] Y. Asahi-Ozaki, Y. Sato, T. Kanno, T. Sata and H. Katano, “Quantitative Analysis of Kaposi Sarcoma-Associated Herpesvirus (KSHV) in KSHV-Associated Diseases,” Journal of Infectious Disease, Vol. 193, No. 6, 2006, pp. 773-782. doi:10.1086/500560
[18] C. Casper, “Defining a Role for Antiviral Drugs in the Treatment of Persons with HHV-8 Infection,” Herpes, Vol. 13, No. 2, 2006, pp. 42-47.
[19] E. Kadyrova, V. Lacoste, R. Duprez, K. Pozharissky, V. Molochkov, M. Huerre, et al., “Molecular Epidemiology of Kaposi’s Sarcoma-Associated Herpesvirus/Human Herpesvirus 8 Strains from Russian Patients with Classic, Posttransplant, and AIDS-Associated Kaposi’s Sarcoma,” Journal of Medical Virology, Vol. 71, No. 4, 2003, pp. 548-556. doi:10.1002/jmv.10530
[20] O. Cassar, M. L. Blondot, S. Mohanna, G. Jouvion, F. Bravo, V. Maco, et al., “Human Herpesvirus 8 Genotype E in Patients with Kaposi Sarcoma, Peru,” Emerging Infectious Diseases, Vol. 16, No. 9, 2010, pp. 1459-1462. doi:10.3201/eid1609.100381
[21] R. J. Biggar, D. Whitby, V. Marshall, A. C. Linhares and F. Black, “Human Herpesvirus 8 in Brazilian Amerindians: A Hyper-Endemic Population with a New Subtype,” Journal of Infectious Diseases, Vol. 181, No. 5, 2000, pp. 1562-1568. doi:10.1086/315456
[22] R. Alegre, J. Moscoso, J. Martinez-Laso, M. Martin-Villa, J. Suarez, A. Moreno, et al., “HLA Genes in Cubans and the Detection of Amerindian Alleles,” Molecular Immunology, Vol. 44, No. 9, 2007, pp. 2426-2435. doi:10.1016/j.molimm.2006.10.017
[23] V. Kouri, P. A. Martinez, B. Acosta, M. E. Rodriguez, O. Blanco, V. Capo, et al., “First report of Kaposi’s Sarcoma-Associated Herpesvirus DNA Sequences from Cuban Kaposi’s Sarcoma Patients without HIV Infection,” Aids, Vol. 21, No. 15, 2007, pp. 2113-2115. doi:10.1097/QAD.0b013e3282f01cc6
[24] E. Cesarman, “Gammaherpesvirus and Lymphoproliferative Disorders in Immunocompromised Patients,” Cancer Letters, Vol. 305, No. 2, 2011, pp. 163-174. doi:10.1016/j.canlet.2011.03.003
[25] A. D’Antonio, M. Addesso, D. Memoli, P. Liguori, R. Cuomo, A. Boscaino, et al., “Lymph Node-Based Disease and HHV-8/KSHV Infection in HIV Seronegative Patients: Report of Three New Cases of a Heterogeneous Group of Diseases,” International Journal of Hematology, Vol. 93, No. 6, 2011, pp. 795-801. doi:10.1007/s12185-011-0849-0
[26] A. Chadburn, E. Hyjek, S. Mathew, E. Cesarman, J. Said and D. M. Knowles, “KSHV-Positive Solid Lymphomas Represent an Extra-Cavitary Variant of Primary Effusion Lymphoma,” The American Journal of Surgical Pathology, Vol. 28, No. 11, 2004, pp. 1401-1416. doi:10.1097/01.pas.0000138177.10829.5c
[27] E. A. Engels, S. M. Mbulaiteye, E. Othieno, M. Gomez, S. Mathew, E. Cesarman, et al., “Kaposi Sarcoma-Associated Herpesvirus in Non-Hodgkin Lymphoma and Reactive Lymphadenopathy in Uganda,” Human Pathology, Vol. 38, No. 2, 2007, pp. 308-314. doi:10.1016/j.humpath.2006.08.009
[28] V. Lacoste, E. Kadyrova, I. Chistiakova, V. Gurtsevitch, J. G. Judde and A. Gessain, “Molecular Characterization of Kaposi’s Sarcoma-Associated Herpesvirus/Human Herpesvirus-8 Strains from Russia,” Journal of General Virology, Vol. 81, No. P5, 2000, pp. 1217-1222.
[29] J. Zong, D. M. Ciufo, R. Viscidi, L. Alagiozoglou, S. Tyring, P. Rady, et al., “Genotypic Analysis at Multiple Loci across Kaposi’s Sarcoma Herpesvirus (KSHV) DNA Molecules: Clustering Patterns, Novel Variants and Chimerism,” Journal of Clinical Virology, Vol. 23, No. 3, 2002, pp. 119-148. doi:10.1016/S1386-6532(01)00205-0
[30] L. A. Dourmishev, A. L. Dourmishev, D. Palmeri, R. A. Schwartz and D. M. Lukac, “Molecular Genetics of Kaposi’s Sarcoma-Associated Herpesvirus (Human Herpesvirus-8) Epidemiology and Pathogenesis,” Microbiology and Molecular Biology Reviews, Vol. 67, No. 2, 2003, pp. 175-212. doi:10.1128/MMBR.67.2.175-212.2003
[31] E. Oksenhendler, D. Cazals-Hatem, T. F. Schulz, V. Barateau, L. Grollet, J. Sheldon, et al., “Transient Angiolymphoid Hyperplasia and Kaposi’s Sarcoma after Primary Infection with Human Herpesvirus 8 in a Patient with Human Immunodeficiency Virus Infection,” New England Journal of Medicine, Vol. 338, No. 22, 1998, pp. 1585-1590. doi:10.1056/NEJM199805283382204
[32] M. Luppi, P. Barozzi, V. Rasini, G. Riva, A. Re, G. Rossi, et al., “Severe Pancytopenia and Hemophagocytosis after HHV-8 Primary Infection in a Renal Transplant Patient Successfully Treated with Foscarnet,” Transplantation, Vol. 74, No. 1, 2002, pp. 131-132. doi:10.1097/00007890-200207150-00023
[33] O. Thaunat, M. F. Mamzer-Bruneel, F. Agbalika, F. Valensi, M. Venditto, C. Lebbe, et al., “Severe Human Herpesvirus-8 Primary Infection in a Renal Transplant Patient Successfully Treated with Anti-CD20 Monoclonal Antibody,” Blood, Vol. 107, No. 7, 2006, pp. 3009-3010. doi:10.1182/blood-2005-08-3213
[34] M. Andreoni, L. Sarmati, E. Nicastri, G. El Sawaf, M. El Zalabani, I. Uccella, et al., “Primary Human Herpesvirus 8 Infection in Immunocompetent Children,” Jama, Vol. 287, No. 10, 2002, pp. 1295-300. doi:10.1001/jama.287.10.1295
[35] F. C. Kasolo, J. Spinks, H. Bima, M. Bates and U. A. Gompels, “Diverse Genotypes of Kaposi’s Sarcoma Associated Herpesvirus (KSHV) Identified in Infant Blood Infections in African Childhood-KS and HIV/AIDS Endemic Region,” Journal of Medical Virology, Vol. 79, No. 10, 2007, pp. 1555-1556. doi:10.1002/jmv.20952

comments powered by Disqus

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.